175 related articles for article (PubMed ID: 36275670)
1. Tumor microenvironment features decipher the outperformance of neoadjuvant immunochemotherapy over chemotherapy in resectable non-small cell lung cancer.
Cai W; Jing M; Gu Y; Bei T; Zhao X; Chen S; Wen J; Gao J; Wu C; Xue Z
Front Immunol; 2022; 13():984666. PubMed ID: 36275670
[TBL] [Abstract][Full Text] [Related]
2. Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non-small-cell lung cancer.
Han R; Zhang Y; Wang T; Xiao H; Luo Z; Shen C; Li J; Zhao C; Li L; Zhu M; Du H; Tang H; Ma Z; Wang Y; He Y
Cancer Sci; 2023 Jun; 114(6):2569-2583. PubMed ID: 36880750
[TBL] [Abstract][Full Text] [Related]
3. Pre-existing tumor host immunity characterization in resected non-small cell lung cancer.
Rocha P; Rodrigo M; Moliner L; Menendez S; Masfarré L; Navarro N; Del Rey-Vergara R; Galindo-Campos M; Taus Á; Giner M; Sanchez I; Rodríguez-Fuster A; Aguiló R; Chalela R; Sánchez-Font A; Belda J; Curull V; Pijuan L; Casadevall D; Clavé S; Bellosillo B; Perera-Bel J; Comerma L; Arriola E
Lung Cancer; 2023 Jul; 181():107257. PubMed ID: 37263182
[TBL] [Abstract][Full Text] [Related]
4. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
[TBL] [Abstract][Full Text] [Related]
5. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.
Parra ER; Villalobos P; Behrens C; Jiang M; Pataer A; Swisher SG; William WN; Zhang J; Lee J; Cascone T; Heymach JV; Forget MA; Haymaker C; Bernatchez C; Kalhor N; Weissferdt A; Moran C; Zhang J; Vaporciyan A; Gibbons DL; Sepesi B; Wistuba II
J Immunother Cancer; 2018 Jun; 6(1):48. PubMed ID: 29871672
[TBL] [Abstract][Full Text] [Related]
6. Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC.
Rocha P; Zhang J; Laza-Briviesca R; Cruz-Bermúdez A; Bota-Rabassedas N; Sanchez-Espiridon B; Yoshimura K; Behrens C; Lu W; Tang X; Pataer A; Parra ER; Haymaker C; Fujimoto J; Swisher SG; Heymach JV; Gibbons DL; Lee JJ; Sepesi B; Cascone T; Solis LM; Provencio M; Wistuba II; Kadara H
Clin Cancer Res; 2022 Jun; 28(11):2461-2473. PubMed ID: 35394499
[TBL] [Abstract][Full Text] [Related]
7. Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer.
Zheng N; Zhang Y; Zeng Y; Ma Q; Zhang R; Zhao Q; Lu C; Tian J; Wang Z; Tang H; Luo N; Xiao H; He Y; Wu F; Li L
Target Oncol; 2023 Jul; 18(4):625-636. PubMed ID: 37351800
[TBL] [Abstract][Full Text] [Related]
8. Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer.
Ma T; Wen T; Cheng X; Wang Y; Wei P; Yang B; Yi L; Wang X; Yan Z; Wang J; Liu Z
Lung Cancer; 2022 Oct; 172():43-52. PubMed ID: 35988509
[TBL] [Abstract][Full Text] [Related]
9. A real-world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non-small cell lung cancer.
Zhang B; Xiao H; Pu X; Zhou C; Yang D; Li X; Wang W; Xiao Q
Cancer Med; 2023 Jan; 12(1):274-286. PubMed ID: 35621048
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant immunotherapy in patients with pulmonary lymphoepithelioma-like carcinoma.
Hong HZ; Li JK; Zhang JT; Li HJ; Peng LS; Wu YL; Zhong WZ
Lung Cancer; 2023 Jul; 181():107220. PubMed ID: 37263181
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter, retrospective study.
Wang X; Wang X; Hui B; Cai J; Zhao H; Qiao B; Duan J; Chen K; Wang J; Lei J; Yang F
Transl Lung Cancer Res; 2024 Apr; 13(4):849-860. PubMed ID: 38736498
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant PD-1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung.
Feng Y; Sun W; Zhang J; Wang Y; Chen J; Liu X; Wang L; Li S; Lv C; Lu F; Zhang J; Hong Y; Xiao S; Wang T; Jiao R; Wang Z; Qi L; Li N; Yang Y; Lin D; Fang J
Thorac Cancer; 2022 Feb; 13(3):442-452. PubMed ID: 34913597
[TBL] [Abstract][Full Text] [Related]
13. To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment.
Yehan Z; Sheng Q; Hong Y; Jiayu L; Jun H; Juan J; Min S; Jiaxin Y; Shangzhi H; Yi W; Qifeng W; Xuefeng L; Wenwu H; Xueyan C; Yang L; Zongyao H
Front Immunol; 2024; 15():1312380. PubMed ID: 38726002
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy is linked to an amended anti-tumorigenic microenvironment in gastric cancer.
Huan X; Zou K; Zhang P; Ding H; Luo C; Xiang C; Xu S; Zhuang Y; Wu C; Wang Y; Wu X; Chen C; Zhang J; Yao X; Liu F; Liu S; Wu Z
Int Immunopharmacol; 2024 Jan; 127():111352. PubMed ID: 38091833
[TBL] [Abstract][Full Text] [Related]
15. Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis.
Chen Y; Qin J; Wu Y; Lin Q; Wang J; Zhang W; Liang F; Hui Z; Zhao M; Wang J
Int J Surg; 2023 Sep; 109(9):2794-2807. PubMed ID: 37247009
[TBL] [Abstract][Full Text] [Related]
16. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
Casarrubios M; Provencio M; Nadal E; Insa A; Del Rosario García-Campelo M; Lázaro-Quintela M; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé R; Viñolas N; Barneto Aranda I; Massuti B; Sierra-Rodero B; Martinez-Toledo C; Fernández-Miranda I; Serna-Blanco R; Romero A; Calvo V; Cruz-Bermúdez A
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171009
[TBL] [Abstract][Full Text] [Related]
17. Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer.
Alì G; Poma AM; Di Stefano I; Zirafa CC; Lenzini A; Martinelli G; Romano G; Chella A; Baldini E; Melfi F; Fontanini G
Front Oncol; 2023; 13():1115156. PubMed ID: 36845706
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis.
Deng H; Zhao Y; Cai X; Chen H; Cheng B; Zhong R; Li F; Xiong S; Li J; Liu J; He J; Liang W
Crit Rev Oncol Hematol; 2022 Feb; 170():103582. PubMed ID: 35031441
[TBL] [Abstract][Full Text] [Related]
19. Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study.
Xu F; Zhu H; Xiong D; Wang K; Dong Y; Li L; Yuan S
Thorac Cancer; 2024 Jan; 15(2):172-181. PubMed ID: 38057283
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World).
Yang Z; Wang S; Yang H; Jiang Y; Zhu L; Zheng B; Fu H; Ma J; Xie H; Wang Z; He H; Xia C; Li R; Xu J; Han J; Huang X; Li Y; Zhao B; Ni C; Xing H; Chen Y; Wang J; Jiang Y; Song Y; Mao Y; Chen C; Yao F; Zhang G; Hu J; Xue Q; Gao S; He J;
J Thorac Cardiovasc Surg; 2024 Feb; ():. PubMed ID: 38342430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]